Raymond James & Associates Adaptimmune Therapeutics PLC Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	BUY	$0.83 - $1.47 $8,480 - $15,020	10,218 New	10,218 $10,000
Q4 2023 Jan 16, 2024	SELL	$0.43 - $0.79 $64 - $119	-151 Reduced 1.46%	10,218 $8,000
Q3 2023 Oct 24, 2023	SELL	$0.73 - $1.04 $58 - $83	-80 Reduced 0.77%	10,369 $8,000
Q2 2023 Jul 25, 2023	SELL	$0.9 - $1.51 $764 - $1,281	-849 Reduced 7.51%	10,449 $9,000
Q1 2023 Apr 14, 2023	BUY	$1.06 - $2.16 $1,325 - $2,700	1,250 Added 12.44%	11,298 $12,000
Q4 2022 Feb 08, 2023	SELL	$1.05 - $2.53 $551 - $1,328	-525 Reduced 4.97%	10,048 $14,000
Q1 2022 May 11, 2022	BUY	$1.73 - $4.06 $18,291 - $42,926	10,573 New	10,573 $22,000
Q3 2020 Nov 04, 2020	SELL	$7.66 - $10.78 $79,671 - $112,122	-10,401 Closed	0 $0
Q2 2020 Jul 28, 2020	SELL	$2.58 - $12.1 $26,832 - $125,840	-10,400 Reduced 50.0%	10,401 $104,000
Q1 2020 Apr 21, 2020	SELL	$1.2 - $4.52 $10,332 - $38,917	-8,610 Reduced 29.27%	20,801 $57,000
Q4 2019 Feb 12, 2020	BUY	$0.72 - $1.43 $2,553 - $5,070	3,546 Added 13.71%	29,411 $35,000
Q3 2019 Nov 07, 2019	BUY	$1.43 - $3.81 $5,333 - $14,211	3,730 Added 16.85%	25,865 $39,000
Q2 2019 Aug 06, 2019	SELL	$3.23 - $5.41 $26,001 - $43,550	-8,050 Reduced 26.67%	22,135 $89,000
Q1 2019 May 06, 2019	BUY	$3.63 - $6.06 $26,422 - $44,110	7,279 Added 31.78%	30,185 $130,000
Q4 2018 Feb 11, 2019	BUY	$3.76 - $14.16 $31,952 - $120,331	8,498 Added 58.98%	22,906 $132,000
Q3 2018 Nov 14, 2018	SELL	$8.27 - $13.56 $9,824 - $16,109	-1,188 Reduced 7.62%	14,408 $195,000
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $99,448 - $131,134	-9,544 Reduced 37.96%	15,596 $185,000
Q1 2018 May 14, 2018	BUY	$7.1 - $11.56 $57,197 - $93,127	8,056 Added 47.16%	25,140 $282,000
Q4 2017 Feb 14, 2018	BUY	$6.68 - $8.74 $114,121 - $149,314	17,084	17,084 $114,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

Matrix Capital Management Company, LP Waltham, MA

37.7M
Shares

$24.9 Million
1.71% of portfolio
Eco R1 Capital, LLC San Francisco, CA

27.4M
Shares

$18.1 Million
1.13% of portfolio
Nea Management Company, LLC Timonium, MD

17.1M
Shares

$11.3 Million
1.24% of portfolio
Baillie Gifford & CO

16.8M
Shares

$11.1 Million
0.01% of portfolio
Long Focus Capital Management, LLC San Juan, PR

13.3M
Shares

$8.78 Million
0.46% of portfolio

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $108M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account